Patents Assigned to Signal Rx Pharmaceuticals, Inc.
  • Thienopyranones as kinase and epigenetic inhibitors
    Patent number: 10308662
    Abstract: The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis, Type 1 or 2 diabetes, obesity, inflammatory disease, or Myc-depenent disorder including by modulating biological processes by the inhibition of PI3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of Formula I-IX (or pharmaceutically acceptable salts thereof) as defined herein.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: June 4, 2019
    Assignee: Signal Rx Pharmaceuticals., Inc.
    Inventors: Donald L. Durden, Guillermo A. Morales, Joseph R. Garlich
  • Thienopyranones as kinase inhibitors
    Patent number: 8557807
    Abstract: The invention, relates to compounds of formula I (or pharmaceutically acceptable salts thereof) as defined herein, pharmaceutical compositions thereof, and their use in manufactures and methods for modulating biological processes including inhibition of kinase activity such as P1-3 kinase.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: October 15, 2013
    Assignee: Signal Rx Pharmaceuticals, Inc.
    Inventors: Guillermo A. Morales, Kevin T. Weber, Jessica M. Newblom, Xiaodong Peng, Jingdong Su, Joseph R. Garlich